Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg; Medical Faculty Heidelberg, University of Heidelberg; Gastroenterologische Schwerpunktpraxis, Dornstadt; AOK Baden-Wuerttemberg, Stuttgart; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg.
Dtsch Arztebl Int. 2020 Jun 19;117(25):423-430. doi: 10.3238/arztebl.2020.0423.
Participation rates in colorectal cancer screening in Germany are low. We therefore investigated the effectiveness of different invitation models for immunological stool blood tests (fecal immunological tests, FITs).
A randomized controlled trial in 50- to 54-year-old clients of the health insurance provider AOK Baden-Wuerttemberg. A total of 17 532 insured persons were randomized to receive: (A) an invitation letter including a FIT (n = 5850); (B) an invitation letter including an option to request a FIT (n = 5844); or (C) an invitation letter only (n = 5838; control group, routine practice). Reminder letters were sent to half the members of groups A and B, selected at random, after 4 weeks. The primary endpoint was the use of a FIT within 1 year of the date of the invitation letter. IRRID: RR2-10.2196/16413. Registration: DRKS00011858.
The invitation letter with a FIT enclosed (A) increased usage from 10% to 29.7% compared with the control group (+19.7% points, p < 0.0001; men: +19.4%, women: +18.8%). The invitation letter with a FIT request option (B) increased usage from 10% to 27.7% (+17.7% points, p < 0.0001; men: +17.7%, women: +17.4%). Reminders increased usage in group A by 7.5% points and in group B by 8.5% points. Participation among women was higher than among men in all groups. The FIT positivity rate was 6.9%. A subsequent colonoscopy was reported for 64.3% of FIT-positive participants, and advanced neoplasia was found in 21.3% of these cases.
Letters of invitation that include a FIT and those that offer low-threshold access to a FIT achieve strong, comparable increases in the usage of FIT in the context of colorectal cancer screening.
德国的结直肠癌筛查参与率较低。因此,我们研究了不同免疫粪便潜血检测(粪便免疫检测,FIT)邀请模型的效果。
在 AOK Baden-Württemberg 健康保险公司的 50 至 54 岁客户中进行了一项随机对照试验。共有 17532 名被保险人随机分为三组:(A)收到附有 FIT 的邀请信(n = 5850);(B)收到附有要求进行 FIT 选项的邀请信(n = 5844);或(C)仅收到邀请信(n = 5838;对照组,常规做法)。四周后,对 A 组和 B 组的一半成员随机发送了提醒信。主要终点是在收到邀请信后的 1 年内使用 FIT。IRRID:RR2-10.2196/16413。注册:DRKS00011858。
与对照组相比(+19.7%,p < 0.0001;男性:+19.4%,女性:+18.8%),附 FIT 的邀请信(A)使使用率从 10%增加到 29.7%。附有 FIT 请求选项的邀请信(B)使使用率从 10%增加到 27.7%(+17.7%,p < 0.0001;男性:+17.7%,女性:+17.4%)。提醒在 A 组增加了 7.5%,在 B 组增加了 8.5%。所有组中女性的参与率均高于男性。FIT 阳性率为 6.9%。对于 FIT 阳性的参与者,有 64.3%报告了随后的结肠镜检查,其中 21.3%发现了晚期肿瘤。
包含 FIT 的邀请信和提供低门槛获取 FIT 的邀请信都能在结直肠癌筛查背景下大幅提高 FIT 的使用率,效果相当。